{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:57:46Z","timestamp":1785499066817,"version":"3.56.0"},"reference-count":210,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,8,20]]},"DOI":"10.1038\/s41416-026-03483-1","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:14:24Z","timestamp":1781356464000},"page":"488-502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paediatric Therapeutic Development Workshop on rhabdomyosarcoma"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-614X","authenticated-orcid":false,"given":"Joseph S.","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Montiel Equihua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Aye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Bisogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"Breunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-7997","authenticated-orcid":false,"given":"Julia","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Danielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Galvez-Cancino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-3724","authenticated-orcid":false,"given":"Patrizia","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3643","authenticated-orcid":false,"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bass","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-3946","authenticated-orcid":false,"given":"Mark E.","family":"Hatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Heenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-6249","authenticated-orcid":false,"given":"Christine M.","family":"Heske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Hettmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hookham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-5813","authenticated-orcid":false,"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2505-7487","authenticated-orcid":false,"given":"Charles","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5858-0488","authenticated-orcid":false,"given":"Javed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Kinnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6664-8318","authenticated-orcid":false,"given":"David","family":"Langenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geffen","family":"Lass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne Mary","family":"Linardic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Metts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Minard-Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbe","family":"Pannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pomella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Rabbitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Rudzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Jack","family":"Shern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Straathof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajkumar","family":"Venkatramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Wachtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Wakeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-1402","authenticated-orcid":false,"given":"Brenda","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5913","authenticated-orcid":false,"given":"Andrew D. J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-8678","authenticated-orcid":false,"given":"Janet","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of LifeArc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Montiel","family":"Equihua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hookham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Kinnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geffen","family":"Lass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew DJ","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Innovative Therapies for Children with Cancer (ITCC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cancer Research UK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Danielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cancer Grand Challenge PROTECT team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"3483_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","volume":"5","author":"SX Skapek","year":"2019","unstructured":"Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5:1.","journal-title":"Nat Rev Dis Primers"},{"key":"3483_CR2","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1200\/JCO.2018.77.9694","volume":"36","author":"DS Hawkins","year":"2018","unstructured":"Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2018;36:2770\u20137.","journal-title":"J Clin Oncol"},{"key":"3483_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/cncr.33334","volume":"127","author":"CM Heske","year":"2021","unstructured":"Heske CM, Chi YY, Venkatramani R, Li M, Arnold MA, Dasgupta R, et al. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: a report from the Soft Tissue Sarcoma Committee of the Children\u2019s Oncology Group. Cancer. 2021;127:946\u201395.","journal-title":"Cancer"},{"key":"3483_CR4","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.21.02981","volume":"40","author":"RA Schoot","year":"2022","unstructured":"Schoot RA, Chisholm JC, Casanova M, Minard-Colin V, Geoerger B, Cameron AL, et al. Metastatic rhabdomyosarcoma: results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and pooled analysis with the Concurrent BERNIE Study. J Clin Oncol. 2022;40:3730\u201340.","journal-title":"J Clin Oncol"},{"key":"3483_CR5","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/cancers15072050","volume":"15","author":"L Tramsen","year":"2023","unstructured":"Tramsen L, Bochennek K, Sparber-Sauer M, Salzmann-Manrique E, Scheer M, Dantonello T, et al. Paediatric Patients With Stage IV rhabdomyosarcoma significantly benefit from long-term maintenance therapy: results of the CWS-IV 2002 and the CWS DOK IV 2004-trials. Cancers. 2023;15:2050.","journal-title":"Cancers"},{"key":"3483_CR6","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S1470-2045(24)00255-9","volume":"25","author":"AA Gupta","year":"2024","unstructured":"Gupta AA, Xue W, Harrison DJ, Hawkins DS, Dasgupta R, Wolden S, et al. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, Phase 3 trial from the Children\u2019s Oncology Group. Lancet Oncol. 2024;25:912\u201392.","journal-title":"Lancet Oncol"},{"key":"3483_CR7","doi-asserted-by":"crossref","unstructured":"Mandeville HC, Bisogno G, Minard-Colin V, Alaggio R, Ben-Arush M, Chargari C, et al. Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial. Cancer. 2024;130:4071\u201384.","DOI":"10.1002\/cncr.35497"},{"key":"3483_CR8","doi-asserted-by":"crossref","unstructured":"Bisogno G, De Salvo GL, Bergeron C, Gallego Melc\u00f3n S, Merks JH, Kelsey A, et al. European Paediatric Soft Tissue Sarcoma Study Group Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, Phase 3 trial. Lancet Oncol. 2019;20:1566\u201375.","DOI":"10.1016\/S1470-2045(19)30617-5"},{"key":"3483_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.32159","volume":"73","author":"AT Heinz","year":"2026","unstructured":"Heinz AT, Sch\u00f6nstein A, Koscielniak E, Ebinger M, Fuchs J, Harrabi S, et al. Children and adolescents with localised non-rhabdomyosarcoma soft tissue sarcoma: results of the CWS-96 and CWS-2002P prospective trials with reclassification of the trial data incorporating the recent soft tissue sarcoma registry. Pediatr Blood Cancer. 2026;73:e32159.","journal-title":"Pediatr Blood Cancer"},{"key":"3483_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/his.14449","volume":"80","author":"NP Agaram","year":"2022","unstructured":"Agaram NP. Evolving classification of rhabdomyosarcoma. Histopathology. 2022;80:98\u2013108.","journal-title":"Histopathology"},{"key":"3483_CR11","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1002\/cncr.24465","volume":"115","author":"S Ognjanovic","year":"2009","unstructured":"Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer. 2009;115:4218\u201326.","journal-title":"Cancer"},{"key":"3483_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/PAP.0b013e3182a92d0d","volume":"20","author":"DM Parham","year":"2013","unstructured":"Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. 2013;20:387\u201397.","journal-title":"Adv Anat Pathol"},{"key":"3483_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000524260","volume":"66","author":"HA Domanski","year":"2022","unstructured":"Domanski HA. The small round cell sarcomas complexities and desmoplastic presentation. Acta Cytol. 2022;66:279\u201394.","journal-title":"Acta Cytol"},{"key":"3483_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41379-018-0120-9","volume":"32","author":"NP Agaram","year":"2019","unstructured":"Agaram NP, LaQuaglia MP, Alaggio R, Zhang L, Fujisawa Y, Ladanyi M, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019;32:27\u201336.","journal-title":"Mod Pathol"},{"key":"3483_CR15","first-page":"6213","volume":"35","author":"J Noujaim","year":"2015","unstructured":"Noujaim J, Thway K, Jones RL, Miah A, Khabra K, Langer R, et al. Adult pleomorphic rhabdomyosarcoma: a multicentre retrospective study. Anticancer Res. 2015;35:6213\u20137.","journal-title":"Anticancer Res"},{"key":"3483_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41379-019-0323-8","volume":"33","author":"F Le Loarer","year":"2020","unstructured":"Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol. 2020;33:404\u201319.","journal-title":"Mod Pathol"},{"key":"3483_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/PAS.0000000000000538","volume":"40","author":"R Alaggio","year":"2016","unstructured":"Alaggio R, Zhang L, Sung YS, Huang SC, Chen CL, Bisogno G, et al. A Molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40:224\u201335.","journal-title":"Am J Surg Pathol"},{"key":"3483_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29511","volume":"69","author":"JH Haduong","year":"2022","unstructured":"Haduong JH, Heske CM, Allen-Rhoades W, Xue W, Teot LA, Rodeberg DA, et al. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children\u2019s Oncology Group clinical trials. Pediatr Blood Cancer. 2022;69:e29511.","journal-title":"Pediatr Blood Cancer"},{"key":"3483_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/cancers16050998","volume":"16","author":"J Chisholm","year":"2024","unstructured":"Chisholm J, Mandeville H, Adams M, Minard-Collin V, Rogers T, Kelsey A, et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: a report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers. 2024;16:998.","journal-title":"Cancers"},{"key":"3483_CR20","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/cncr.35258","volume":"130","author":"GL De Salvo","year":"2024","unstructured":"De Salvo GL, Del Bianco P, Minard-Colin V, Chisholm J, Jenney M, Guillen G, et al. Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram. Cancer. 2024;130:2351\u201360.","journal-title":"Cancer"},{"key":"3483_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35974","volume":"131","author":"G Bisogno","year":"2025","unstructured":"Bisogno G, Sparber-Sauer M, Rodeberg D, Merks JHM, Koscielniak E, Wolden SL, et al. The International Soft Tissue Sarcoma Consortium: the baseline analysis of rhabdomyosarcoma data. Cancer. 2025;131:e35974. https:\/\/doi.org\/10.1002\/cncr.35974.","journal-title":"Cancer"},{"key":"3483_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejca.2022.05.036","volume":"172","author":"S Hettmer","year":"2022","unstructured":"Hettmer S, Linardic CM, Kelsey A, Rudzinski ER, Vokuhl C, Selfe J, et al. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: a consensus view from European paediatric Soft tissue sarcoma Study Group, Children\u2019s Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022;172:367\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.036.","journal-title":"Eur J Cancer"},{"key":"3483_CR23","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/jor.24387","volume":"37","author":"KM Amer","year":"2019","unstructured":"Amer KM, Thomson JE, Congiusta D, Dobitsch A, Chaudhry A, Li M, et al. Epidemiology, incidence, and survival of rhabdomyosarcoma subtypes: SEER and ICES database analysis. J Orthop Res. 2019;37:2226\u201330.","journal-title":"J Orthop Res"},{"key":"3483_CR24","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/cam4.2713","volume":"9","author":"T Butel","year":"2020","unstructured":"Butel T, Karanian M, Pierron G, Orbach D, Ranchere D, Cozic N, et al. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: a report from the French MMT committee. Cancer Med. 2020;9:2698\u2013709.","journal-title":"Cancer Med"},{"key":"3483_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2022.03.022","volume":"168","author":"S Whittle","year":"2022","unstructured":"Whittle S, Venkatramani R, Sch\u00f6nstein A, Pack SD, Alaggio R, Vokuhl C, et al. Congenital spindle cell rhabdomyosarcoma: an international cooperative analysis. Eur J Cancer. 2022;168:56\u201364.","journal-title":"Eur J Cancer"},{"key":"3483_CR26","volume":"14","author":"SU Rab","year":"2022","unstructured":"Rab SU, Bin Naeem S, Baloch NU, Jhatial MA, Waheed M, Fasih S, et al. Baseline characteristics, prognostic factors, and treatment outcomes for adult patients with rhabdomyosarcoma (RMS). Cureus. 2022;14:e32961.","journal-title":"Cureus"},{"key":"3483_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/gcc.23013","volume":"61","author":"ZL Chelsky","year":"2022","unstructured":"Chelsky ZL, Paulson VA, Chen EY. Molecular analysis of 10 pleomorphic rhabdomyosarcomas reveals potential prognostic markers and druggable targets. Genes Chromosomes Cancer. 2022;61:138\u201347.","journal-title":"Genes Chromosomes Cancer"},{"key":"3483_CR28","doi-asserted-by":"crossref","unstructured":"Makimoto A. Optimizing rhabdomyosarcoma treatment in adolescents and young adults. Cancers. 2022;14:2270.","DOI":"10.3390\/cancers14092270"},{"key":"3483_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2353\/ajpath.2009.080631","volume":"174","author":"E Davicioni","year":"2009","unstructured":"Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children\u2019s Oncology Group. Am J Surg Pathol. 2009;174:550\u201364.","journal-title":"Am J Surg Pathol"},{"key":"3483_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.5858\/arpa.2021-0183-RA","volume":"146","author":"R Fan","year":"2022","unstructured":"Fan R, Parham DM, Wang LL. An integrative morphologic and molecular approach for diagnosis and subclassification of rhabdomyosarcoma. Arch Pathol Lab. 2022;146:953\u20139.","journal-title":"Arch Pathol Lab"},{"key":"3483_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29288","volume":"68","author":"D Di Carlo","year":"2021","unstructured":"Di Carlo D, Chargari C, Scoazec JY, Cotteret S, Felix A, Moalla S, et al. PAX3-NCOA1 alveolar rhabdomyosarcoma of the tongue: a rare entity with challenging diagnosis and management. Pediatr Blood Cancer. 2021;68:e29288.","journal-title":"Pediatr Blood Cancer"},{"key":"3483_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100594","volume":"37","author":"JK Dermawan","year":"2024","unstructured":"Dermawan JK, Malik F, Gross JM, Baraban E, Pratilas C, Mneimneh W, et al. Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of \u201cfusion-positive\u201d cases. Mod Pathol. 2024;37:100594.","journal-title":"Mod Pathol"},{"key":"3483_CR33","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1200\/JCO.2009.26.3814","volume":"28","author":"D Williamson","year":"2010","unstructured":"Williamson D, Missiaglia E, de Reyni\u00e8s A, Pierron G, Thuille B, Palenzuela G, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010;28:2151\u20138.","journal-title":"J Clin Oncol"},{"key":"3483_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ajmg.a.61395","volume":"182","author":"B Garren","year":"2020","unstructured":"Garren B, Stephan M, Hogue JS. NRAS associated RASopathy and embryonal rhabdomyosarcoma. Am J Med Genet A. 2020;182:195\u2013200.","journal-title":"Am J Med Genet A"},{"key":"3483_CR35","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1200\/JCO.2009.27.5339","volume":"28","author":"LH Wexler","year":"2010","unstructured":"Wexler LH, Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J Clin Oncol. 2010;28:2126\u20138.","journal-title":"J Clin Oncol"},{"key":"3483_CR36","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1200\/JCO.2007.14.7207","volume":"26","author":"O Oberlin","year":"2008","unstructured":"Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26:2384\u20139.","journal-title":"J Clin Oncol"},{"key":"3483_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.oraloncology.2016.08.017","volume":"61","author":"AA Owosho","year":"2016","unstructured":"Owosho AA, Huang S-C, Chen S, Kashikar S, Estilo CL, Wolden SL, et al. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome. Oral Oncol. 2016;61:89\u201397.","journal-title":"Oral Oncol"},{"key":"3483_CR38","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s43018-022-00414-w","volume":"3","author":"Y Wei","year":"2022","unstructured":"Wei Y, Qin Q, Yan C, Hayes MN, Garcia SP, Xi H, et al. Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma. Nat Cancer. 2022;3:961\u201375.","journal-title":"Nat Cancer"},{"key":"3483_CR39","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1200\/JCO.20.03060","volume":"39","author":"JF Shern","year":"2021","unstructured":"Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, et al. Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium. J Clin Oncol. 2021;39:2859\u201371.","journal-title":"J Clin Oncol"},{"key":"3483_CR40","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.ejca.2015.02.010","volume":"51","author":"RA Schoot","year":"2015","unstructured":"Schoot RA, Slater O, Ronckers CM, Zwinderman AH, Balm AJ, Hartley B, et al. Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. Eur J Cancer. 2015;51:1424\u201334.","journal-title":"Eur J Cancer"},{"key":"3483_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757095","volume":"11","author":"H Zhen","year":"2021","unstructured":"Zhen H, Liu Z, Guan H, Ma J, Wang W, Shen J, et al. Second malignant neoplasms in patients with rhabdomyosarcoma. Front Oncol. 2021;11:757095.","journal-title":"Front Oncol"},{"key":"3483_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35918","volume":"131","author":"L Rossillon","year":"2025","unstructured":"Rossillon L, Thomas-Teinturier C, Orbach D, Tabone M-D, Bertrand A, Ansoborlo S, et al. Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France. Cancer. 2025;131. e3591.","journal-title":"Cancer"},{"key":"3483_CR43","doi-asserted-by":"crossref","unstructured":"Stevens BT, Hatley ME. Developmental heterogeneity of rhabdomyosarcoma. Cold Spring Harb Perspect Med. 2025;15:a041583.","DOI":"10.1101\/cshperspect.a041583"},{"key":"3483_CR44","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1101\/gad.1244004","volume":"18","author":"C Keller","year":"2004","unstructured":"Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: cooperativity of Ink4a\/ARF and Trp53 loss of function. Genes Dev. 2004;18:2614\u201326.","journal-title":"Genes Dev"},{"key":"3483_CR45","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.1158\/0008-5472.CAN-06-3210","volume":"67","author":"CM Linardic","year":"2007","unstructured":"Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 2007;67:6691\u20139.","journal-title":"Cancer Res"},{"key":"3483_CR46","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccr.2012.09.004","volume":"22","author":"ME Hatley","year":"2012","unstructured":"Hatley ME, Tang W, Garcia MR, Finkelstein D, Millay DP, Liu N, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell. 2012;22:536\u201346.","journal-title":"Cancer Cell"},{"key":"3483_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ccell.2017.12.001","volume":"33","author":"CJ Drummond","year":"2018","unstructured":"Drummond CJ, Hanna JA, Garcia MR, Devine DJ, Heyrana AJ, Finkelstein D, et al. Hedgehog pathway drives fusion-negative rhabdomyosarcoma initiated from non-myogenic endothelial progenitors. Cancer Cell. 2018;33:108\u201324.","journal-title":"Cancer Cell"},{"key":"3483_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43044-1","volume":"14","author":"MB Searcy","year":"2023","unstructured":"Searcy MB, Larsen RK 4th, Stevens BT, Zhang Y, Jin H, Drummond CJ, et al. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors. Nat Commun. 2023;14. 7291.","journal-title":"Nat Commun"},{"key":"3483_CR49","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","volume":"4","author":"JF Shern","year":"2014","unstructured":"Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216\u201331.","journal-title":"Cancer Discov"},{"key":"3483_CR50","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1200\/JCO.2002.03.137","volume":"20","author":"PH Sorensen","year":"2002","unstructured":"Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2002;20:2672\u20139.","journal-title":"J Clin Oncol"},{"key":"3483_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00428-019-02676-9","volume":"476","author":"J Leiner","year":"2020","unstructured":"Leiner J, Le Loarer F. The current landscape of rhabdomyosarcomas: an update. Virchows Archiv. 2020;476:97\u2013108.","journal-title":"Virchows Archiv"},{"key":"3483_CR52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/gcc.20864","volume":"50","author":"V Paulson","year":"2011","unstructured":"Paulson V, Chandler G, Rakheja D, Galindo RL, Wilson K, Amatruda JF, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011;50:397\u2013408.","journal-title":"Genes Chromosomes Cancer"},{"key":"3483_CR53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccr.2010.12.023","volume":"19","author":"BP Rubin","year":"2011","unstructured":"Rubin BP, Nishijo K, Chen HI, Yi X, Schuetze DP, Pal R, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011;19:177\u201391.","journal-title":"Cancer Cell"},{"key":"3483_CR54","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/modpathol.2012.222","volume":"26","author":"A Yoshida","year":"2013","unstructured":"Yoshida A, Shibata T, Wakai S, Ushiku T, Tsuta K, Fukayama M, et al. Anaplastic lymphoma kinase status in rhabdomyosarcomas. Mod Pathol. 2013;26:772\u201381.","journal-title":"Mod Pathol"},{"key":"3483_CR55","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1200\/JCO.2005.11.078","volume":"23","author":"D Williamson","year":"2005","unstructured":"Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol. 2005;23:880\u20138.","journal-title":"J Clin Oncol"},{"key":"3483_CR56","doi-asserted-by":"publisher","first-page":"e1005075","DOI":"10.1371\/journal.pgen.1005075","volume":"11","author":"L Chen","year":"2015","unstructured":"Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, et al. Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet. 2015;11:e1005075.","journal-title":"PLoS Genet"},{"key":"3483_CR57","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ccr.2013.11.002","volume":"24","author":"X Chen","year":"2013","unstructured":"Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013;24:710\u201324.","journal-title":"Cancer Cell"},{"key":"3483_CR58","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/PAS.0000000000001702","volume":"45","author":"J Cyrta","year":"2021","unstructured":"Cyrta J, Gauthier A, Karanian M, Vieira AF, Cardoen L, Jehanno N, et al. Infantile rhabdomyosarcomas with VGLL2 rearrangement are not always an indolent disease: a study of 4 aggressive cases with clinical, pathologic, molecular, and radiologic findings. Am J Surg Pathol. 2021;45:854\u201367.","journal-title":"Am J Surg Pathol"},{"key":"3483_CR59","doi-asserted-by":"crossref","unstructured":"A MYOD1 mutation cooperates with PI3K pathway activation in ERMS. Cancer Discov. 2014;4:Of19.","DOI":"10.1158\/2159-8290.CD-RW2014-109"},{"key":"3483_CR60","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jnci\/djaa204","volume":"113","author":"H Li","year":"2021","unstructured":"Li H, Sisodia SD, Martin-Giacalone BA, Khayat MM, Dugan-Perez S, Marquez-Do DA, et al. Germline cancer predisposition variants in pediatric rhabdomyosarcoma: a report from the Children\u2019s Oncology Group. J Natl Cancer Inst. 2021;113:875\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"3483_CR61","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cam4.448","volume":"4","author":"PJ Lupo","year":"2015","unstructured":"Lupo PJ, Danysh HE, Plon SE, Curtin K, Malkin D, Hettmer S, et al. Family history of cancer and childhood rhabdomyosarcoma: a report from the Children\u2019s Oncology Group and the Utah Population Database. Cancer Med. 2015;4:781\u201390.","journal-title":"Cancer Med"},{"key":"3483_CR62","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/modpathol.2011.185","volume":"25","author":"LP Dehner","year":"2012","unstructured":"Dehner LP, Jarzembowski JA, Hill DA. Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations. Mod Pathol. 2012;25:602\u201314.","journal-title":"Mod Pathol"},{"key":"3483_CR63","first-page":"S47","volume":"24","author":"KM Robbins","year":"2013","unstructured":"Robbins KM, Stabley DL, Holbrook J, Gripp KW, Sol-Church K. Uniparental disomy is associated with embryonal rhabdomyosarcoma in Costello Syndrome and nonsyndromic patients: from core-side to bedside and back again. Impact of Core Laboratories on Biomedical Research: J Biomol Tech. 2013;24:S47\u20138.","journal-title":"Impact of Core Laboratories on Biomedical Research: J Biomol Tech"},{"key":"3483_CR64","doi-asserted-by":"crossref","unstructured":"Schmidt A, Behrendt L, Eybe J, Warmann SW, Schleicher S, Fuchs J, et al. The effect of direct and indirect EZH2 Inhibition in rhabdomyosarcoma cell lines. Cancers. 2021;14:41.","DOI":"10.3390\/cancers14010041"},{"key":"3483_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01147-w","volume":"13","author":"S Zoroddu","year":"2021","unstructured":"Zoroddu S, Marchesi I, Bagella L. PRC2: an epigenetic multiprotein complex with a key role in the development of rhabdomyosarcoma carcinogenesis. Clin Epigenetics. 2021;13:156.","journal-title":"Clin Epigenetics"},{"key":"3483_CR66","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1158\/2159-8290.CD-16-1297","volume":"7","author":"BE Gryder","year":"2017","unstructured":"Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, et al. PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability. Cancer Discov. 2017;7:884\u201399.","journal-title":"Cancer Discov"},{"key":"3483_CR67","doi-asserted-by":"publisher","first-page":"79342","DOI":"10.18632\/oncotarget.12688","volume":"7","author":"F Megiorni","year":"2016","unstructured":"Megiorni F, Camero S, Ceccarelli S, McDowell HP, Mannarino O, Marampon F, et al. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation. Oncotarget. 2016;7:79342\u201356.","journal-title":"Oncotarget"},{"key":"3483_CR68","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1172\/JCI85057","volume":"126","author":"M B\u00f6hm","year":"2016","unstructured":"B\u00f6hm M, Wachtel M, Marques JG, Streiff N, Laubscher D, Nanni P, et al. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. J Clin Investing. 2016;126:4237\u201349.","journal-title":"J Clin Investing"},{"key":"3483_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101996","volume":"24","author":"S Singh","year":"2021","unstructured":"Singh S, Abu-Zaid A, Lin W, Low J, Abdolvahabi A, Jin H, et al. 17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma. iScience. 2021;24:101996.","journal-title":"iScience"},{"key":"3483_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq2096","volume":"14","author":"S Singh","year":"2022","unstructured":"Singh S, Abu-Zaid A, Jin H, Fang J, Wu Q, Wang T, et al. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Sci Transl Med. 2022;14:eabq2096.","journal-title":"Sci Transl Med"},{"key":"3483_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1333129","volume":"14","author":"I Martynov","year":"2024","unstructured":"Martynov I, Dhaka L, Wilke B, Hoyer P, Vahdad MR, Seitz G. Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside. Front Oncol. 2024;14:1333129.","journal-title":"Front Oncol"},{"key":"3483_CR72","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fonc.2013.00183","volume":"3","author":"AR Hinson","year":"2013","unstructured":"Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol. 2013;3:183.","journal-title":"Front Oncol"},{"key":"3483_CR73","unstructured":"St Jude Visualization Community. Epigenetic Landscape of Rhabdomyosarcoma Subtypes. https:\/\/viz.stjude.cloud\/st-jude-childrens-research-hospital\/visualization\/epigenetic-landscape-of-rhabdomyosarcoma-subtypes~67."},{"key":"3483_CR74","unstructured":"Childhood Solid Tumor Network. https:\/\/www.stjude.org\/research\/why-st-jude\/data-tools\/childhood-solid-tumor-network.html."},{"key":"3483_CR75","unstructured":"ITCCP4. https:\/\/itccp4.com."},{"key":"3483_CR76","unstructured":"National Cancer Institute. Childhood Cancer Initiative Data Hub. https:\/\/ccdi.cancer.gov\/."},{"key":"3483_CR77","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s42003-023-05320-0","volume":"6","author":"ME Marques Da Costa","year":"2023","unstructured":"Marques Da Costa ME, Zaidi S, Scoazec JY, Droit R, Lim WC, Marchais A, et al. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors. Commun Biol. 2023;6:949.","journal-title":"Commun Biol"},{"key":"3483_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109781","volume":"27","author":"C Tlemsani","year":"2024","unstructured":"Tlemsani C, Heske CM, Elloumi F, Pongor L, Khandagale P, Varma S, et al. Sarcoma_CellminerCDB: a tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines. iScience. 2024;27:109781.","journal-title":"iScience"},{"key":"3483_CR79","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3892\/or.2010.1067","volume":"24","author":"G Seitz","year":"2010","unstructured":"Seitz G, Pfeiffer M, Fuchs J, Warmann SW, Leuschner I, Vokuhl C, et al. Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep. 2010;24:1067\u201372.","journal-title":"Oncol Rep"},{"key":"3483_CR80","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216001","volume":"14","author":"MT Meister","year":"2022","unstructured":"Meister MT, Groot Koerkamp MJA, de Souza T, Breunis WB, Frazer-Mendelewska E, Brok M, et al. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes. EMBO Mol Med. 2022;14:e16001.","journal-title":"EMBO Mol Med"},{"key":"3483_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101212","volume":"4","author":"M Tian","year":"2023","unstructured":"Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, et al. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell Rep Med. 2023;4:101212.","journal-title":"Cell Rep Med"},{"key":"3483_CR82","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1158\/1078-0432.CCR-10-3063","volume":"18","author":"LE Crose","year":"2012","unstructured":"Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res. 2012;18:3780\u201390.","journal-title":"Clin Cancer Res"},{"key":"3483_CR83","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1038\/s41416-022-01973-6","volume":"12","author":"E Fiorito","year":"2022","unstructured":"Fiorito E, Szybowska P, Haugsten EM, Kostas M, \u00d8y GF, Wiedlocha A, et al. Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma. Br J Cancer. 2022;12:1939\u201353.","journal-title":"Br J Cancer"},{"key":"3483_CR84","first-page":"3395","volume":"119","author":"JG Taylor","year":"2009","unstructured":"Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Investig. 2009;119:3395\u2013407.","journal-title":"J Clin Investig"},{"key":"3483_CR85","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1038\/s41388-017-0122-y","volume":"37","author":"T McKinnon","year":"2018","unstructured":"McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, et al. Functional screening of FGFR4-driven tumorigenesis identifies PI3K\/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma. Oncogene. 2018;37:2630\u201344.","journal-title":"Oncogene"},{"key":"3483_CR86","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/1535-7163.MCT-22-0059","volume":"21","author":"PM Sullivan","year":"2022","unstructured":"Sullivan PM, Kumar R, Li W, Hoglund V, Wang L, Zhang Y, et al. FGFR4-targeted chimeric antigen receptors combined with anti-myeloid polypharmacy effectively treat orthotopic rhabdomyosarcoma. Mol Cancer Ther. 2022;21:1608\u201321.","journal-title":"Mol Cancer Ther"},{"key":"3483_CR87","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41417-024-00823-2","volume":"31","author":"W Xiao","year":"2024","unstructured":"Xiao W, Xu L, Wang J, Yu K, Xu B, Que Y, et al. FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma. Cancer Gene Ther. 2024;31:1571\u201384.","journal-title":"Cancer Gene Ther"},{"key":"3483_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50251-x","volume":"15","author":"M Tian","year":"2024","unstructured":"Tian M, Wei JS, Cheuk AT, Milewski D, Zhang Z, Kim YY, et al. CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma. Nat Commun. 2024;15:6222.","journal-title":"Nat Commun"},{"key":"3483_CR89","doi-asserted-by":"crossref","unstructured":"Alijaj N, Moutel S, Gouveia ZL, Gray M, Roveri M, Dzhumashev D, et al. Novel FGFR4-targeting single-domain antibodies for multiple targeted therapies against rhabdomyosarcoma. Cancers. 2020;12:3313.","DOI":"10.3390\/cancers12113313"},{"key":"3483_CR90","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13046-023-02838-3","volume":"42","author":"A Timpanaro","year":"2023","unstructured":"Timpanaro A, Piccand C, Dzhumashev D, Anton-Joseph S, Robbi A, Moser J, et al. CD276-CAR T cells and Dual-CAR T cells targeting CD276\/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models. J Exp Clin Cancer Res. 2023;42:293.","journal-title":"J Exp Clin Cancer Res"},{"key":"3483_CR91","doi-asserted-by":"crossref","unstructured":"Timpanaro A, Piccand C, Uldry AC, Bode PK, Dzhumashev D, Sala R, et al. Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma. Int J Mol Sci. 2023;24:2601.","DOI":"10.3390\/ijms24032601"},{"key":"3483_CR92","doi-asserted-by":"crossref","unstructured":"Lavoie RR, Gargollo PC, Ahmed ME, Kim Y, Baer E, Phelps DA, et al. Surfaceome profiling of rhabdomyosarcoma reveals B7-H3 as a mediator of immune evasion. Cancers. 2021;13:4528.","DOI":"10.3390\/cancers13184528"},{"key":"3483_CR93","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/cncr.28728","volume":"120","author":"AS Pappo","year":"2014","unstructured":"Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, et al. A Phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014;120:2448\u201356.","journal-title":"Cancer"},{"key":"3483_CR94","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/pbc.24605","volume":"61","author":"B Weigel","year":"2014","unstructured":"Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2014;61:452\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"3483_CR95","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/ijc.28800","volume":"135","author":"M Wachtel","year":"2014","unstructured":"Wachtel M, Rakic J, Okoniewski M, Bode P, Niggli F, Sch\u00e4fer BW. FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells. Int J Cancer. 2014;135:1543\u201352.","journal-title":"Int J Cancer"},{"key":"3483_CR96","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1038\/onc.2010.364","volume":"29","author":"LH Mayeenuddin","year":"2010","unstructured":"Mayeenuddin LH, Yu Y, Kang Z, Helman LJ, Cao L. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L). Oncogene. 2010;29:6367\u201377.","journal-title":"Oncogene"},{"key":"3483_CR97","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1038\/onc.2013.509","volume":"33","author":"Z Kang","year":"2014","unstructured":"Kang Z, Yu Y, Zhu YJ, Davis S, Walker R, Meltzer PS, et al. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. Oncogene. 2014;33:5697\u2013705.","journal-title":"Oncogene"},{"key":"3483_CR98","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1158\/1078-0432.CCR-22-1646","volume":"29","author":"KE Hebron","year":"2023","unstructured":"Hebron KE, Wan X, Roth JS, Liewehr DJ, Sealover NE, Frye WJE, et al. The Combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models. Clin Cancer Res. 2023;29:472\u201387.","journal-title":"Clin Cancer Res"},{"key":"3483_CR99","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/ng.2969","volume":"46","author":"S Kohsaka","year":"2014","unstructured":"Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46:595\u2013600.","journal-title":"Nat Genet"},{"key":"3483_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112013","volume":"4","author":"S Watson","year":"2023","unstructured":"Watson S, LaVigne CA, Xu L, Surdez D, Cyrta J, Calderon D, et al. VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis. Cell Rep. 2023;4:112013.","journal-title":"Cell Rep"},{"key":"3483_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20386-8","volume":"12","author":"S Pomella","year":"2021","unstructured":"Pomella S, Sreenivas P, Gryder BE, Wang L, Milewski D, Cassandri M, et al. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma. Nat Commun. 2021;12:192.","journal-title":"Nat Commun"},{"key":"3483_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44130-0","volume":"14","author":"S Pomella","year":"2023","unstructured":"Pomella S, Cassandri M, D\u2019Archivio L, Porrazzo A, Cossetti C, Phelps D, et al. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting. Nat Commun. 2023;14:8373. https:\/\/doi.org\/10.1038\/s41467-023-44130-0.","journal-title":"Nat Commun"},{"key":"3483_CR103","doi-asserted-by":"publisher","first-page":"e19214","DOI":"10.7554\/eLife.19214","volume":"6","author":"IM Tenente","year":"2017","unstructured":"Tenente IM, Hayes MN, Ignatius MS, McCarthy K, Yohe M, Sindiri S, et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. eLife. 2017;6:e19214 https:\/\/doi.org\/10.7554\/eLife.19214.","journal-title":"eLife"},{"key":"3483_CR104","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025;25:59\u201373.","journal-title":"Nat Rev Cancer"},{"key":"3483_CR105","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.molcel.2012.05.046","volume":"47","author":"VD Soleimani","year":"2012","unstructured":"Soleimani VD, Yin H, Jahani-Asl A, Ming H, Kockx CE, van Ijcken WF, et al. Snail regulates MyoD binding-site occupancy to direct enhancer switching and differentiation-specific transcription in myogenesis. Mol Cell. 2012;47:457\u201368.","journal-title":"Mol Cell"},{"key":"3483_CR106","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade8184","volume":"9","author":"AM Shah","year":"2023","unstructured":"Shah AM, Guo L, Morales MG, Jaichander P, Chen K, Huang H, et al. TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma. Sci Adv. 2023;9:eade8184. https:\/\/doi.org\/10.1126\/sciadv.ade8184.","journal-title":"Sci Adv"},{"key":"3483_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110323","volume":"38","author":"JY Hsu","year":"2022","unstructured":"Hsu JY, Danis EP, Nance S, Jaichander P, Chen K, Huang H, et al. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state. Cell Rep. 2022;38:110323. https:\/\/doi.org\/10.1016\/j.celrep.2022.110323.","journal-title":"Cell Rep"},{"key":"3483_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-2-7","volume":"2","author":"KL Macquarrie","year":"2012","unstructured":"Macquarrie KL, Yao Z, Young JM, Cao Y, Tapscott SJ. miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells. Skelet Muscle. 2012;2:7. https:\/\/doi.org\/10.1186\/2044-5040-2-7.","journal-title":"Skelet Muscle"},{"key":"3483_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113149","volume":"28","author":"AR Oles","year":"2025","unstructured":"Oles AR, Yu PY, Udeme AA, Sharma S, Londhe P, Pryce BR, et al. MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. iScience. 2025;28:113149.","journal-title":"iScience"},{"key":"3483_CR110","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3389\/fped.2018.00378","volume":"6","author":"N Ragab","year":"2018","unstructured":"Ragab N, Viehweger F, Bauer J, Geyer N, Yang M, Seils A, et al. Canonical WNT\/\u03b2-catenin signaling plays a subordinate role in rhabdomyosarcomas. Front Pediatr. 2018;6:378.","journal-title":"Front Pediatr"},{"key":"3483_CR111","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.stem.2018.02.002","volume":"22","author":"MN Hayes","year":"2018","unstructured":"Hayes MN, McCarthy K, Jin A, Oliveira ML, Iyer S, Garcia SP, et al. Vangl2\/RhoA signaling pathway regulates stem cell self-renewal programs and growth in rhabdomyosarcoma. Cell Stem Cell. 2018;22:414\u201327.","journal-title":"Cell Stem Cell"},{"key":"3483_CR112","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","volume":"150","author":"Z Debebe","year":"2015","unstructured":"Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharmacol Ther. 2015;150:143\u20138.","journal-title":"Pharmacol Ther"},{"key":"3483_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105350","volume":"299","author":"R Riquelme","year":"2023","unstructured":"Riquelme R, Li L, Gambrill A, Barria A. ROR2 homodimerization is sufficient to activate a neuronal Wnt\/calcium signaling pathway. J Biol Chem. 2023;299:105350. https:\/\/doi.org\/10.1016\/j.jbc.2023.105350.","journal-title":"J Biol Chem"},{"key":"3483_CR114","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcb.21848","volume":"105","author":"Y Liu","year":"2008","unstructured":"Liu Y, Rubin B, Bodine PV, Billiard J. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem. 2008;105:497\u2013502. https:\/\/doi.org\/10.1002\/jcb.21848.","journal-title":"J Cell Biochem"},{"key":"3483_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.891763","volume":"10","author":"M Endo","year":"2022","unstructured":"Endo M, Kamizaki K, Minami Y. The Ror-family receptors in development, tissue regeneration and age-related disease. Front Cell Dev Biol. 2022;10:891763. https:\/\/doi.org\/10.3389\/fcell.2022.891763.","journal-title":"Front Cell Dev Biol"},{"key":"3483_CR116","doi-asserted-by":"publisher","unstructured":"Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009;100. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01165.x.","DOI":"10.1111\/j.1349-7006.2009.01165.x"},{"key":"3483_CR117","doi-asserted-by":"publisher","first-page":"395.","DOI":"10.1186\/s13046-021-02187-z","volume":"40","author":"K Menck","year":"2021","unstructured":"Menck K, Heinrichs S, Wlochowitz D, Sitte M, Noeding H, Janshoff A, et al. WNT11\/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer. J Exp Clin Cancer Res. 2021;40:395. https:\/\/doi.org\/10.1186\/s13046-021-02187-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"3483_CR118","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1172\/JCI83535","volume":"126","author":"J Yu","year":"2016","unstructured":"Yu J, Chen L, Cui B, Widhopf GF 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Investig. 2016;126:585\u201398.","journal-title":"J Clin Investig"},{"key":"3483_CR119","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1038\/onc.2009.175","volume":"28","author":"M Enomoto","year":"2009","unstructured":"Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a\/Ror2 signaling. Oncogene. 2009;28:3197\u2013208.","journal-title":"Oncogene"},{"key":"3483_CR120","doi-asserted-by":"publisher","unstructured":"Nishita M, Park SY, Nishio T, Kamizaki K, Wang Z, Tamada K, et al. Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness. Sci Rep. 2017;7. https:\/\/doi.org\/10.1038\/s41598-016-0028-x.","DOI":"10.1038\/s41598-016-0028-x"},{"key":"3483_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.32","volume":"5","author":"CE Henry","year":"2016","unstructured":"Henry CE, Llamosas E, Djordjevic A, Hacker NF, Ford CE. Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis. 2016;5:e226. https:\/\/doi.org\/10.1038\/oncsis.2016.32.","journal-title":"Oncogenesis"},{"key":"3483_CR122","unstructured":"A Phase 2 Open Label Study of BA3021 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. https:\/\/clinicaltrials.gov\/study\/NCT05271604."},{"key":"3483_CR123","unstructured":"Safety and efficacy of CCT301 CAR-T in adult subjects with recurrent or refractory Stage IV renal cell carcinoma. https:\/\/clinicaltrials.gov\/study\/NCT03393936."},{"key":"3483_CR124","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2490078","volume":"17","author":"HW Chang","year":"2025","unstructured":"Chang HW, Frey G, Wang J, Kamizaki K, Wang Z, Tamada K, et al. Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate. MAbs. 2025;17:2490078.","journal-title":"MAbs"},{"key":"3483_CR125","doi-asserted-by":"publisher","first-page":"A033","DOI":"10.1158\/1538-7445.PEDIATRIC25-A033","volume":"85","author":"J Lee","year":"2025","unstructured":"Lee J, Mathavarajah S, Wei Y, Corchete Sanchez LA, Kannambadi DD, Rheinbay E, et al. Targeting ROR2 with an antibody-drug conjugate to overcome MYOD1L122R-driven therapy resistance in rhabdomyosarcoma. Cancer Res. 2025;85:A033.","journal-title":"Cancer Res"},{"key":"3483_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110715","volume":"301","author":"E Yaz\u0131c\u0131","year":"2025","unstructured":"Yaz\u0131c\u0131 E, McIntyre J. The complex network of p300\/CBP regulation: interactions, post-translational modifications, and therapeutic implications. J Biol Chem. 2025;301:110715.","journal-title":"J Biol Chem"},{"key":"3483_CR127","doi-asserted-by":"crossref","unstructured":"Asante Y, Benischke K, Osman I, Ngo QA, Wurth J, Laubscher D, et al. PAX3-FOXO1 uses its activation domain to recruit CBP\/P300 and shape RNA Pol2 cluster distribution. Nat Commun. 2023;14:8361.","DOI":"10.1038\/s41467-023-43780-4"},{"key":"3483_CR128","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.98386","volume":"13","author":"S Guo","year":"2025","unstructured":"Guo S, Hu X, Cotton JL, Ma L, Li Q, Cui J, et al. VGLL2 and TEAD1 fusion proteins drive YAP\/TAZ-independent tumorigenesis by engaging p300. eLife. 2025;13:RP98386.","journal-title":"eLife"},{"key":"3483_CR129","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57683","volume":"9","author":"A Pal","year":"2020","unstructured":"Pal A, Leung JY, Ang GCK, Rao VK, Pignata L, Lim HJ, et al. EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma. eLife. 2020;9:e57683.","journal-title":"eLife"},{"key":"3483_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47102-0","volume":"15","author":"NAM Shendy","year":"2024","unstructured":"Shendy NAM, Bikowitz M, Sigua LH, Zhang Y, Mercier A, Khashana Y, et al. Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300\/CBP inhibition. Nat Commun. 2024;15:3483.","journal-title":"Nat Commun"},{"key":"3483_CR131","unstructured":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies. https:\/\/clinicaltrials.gov\/study\/NCT04068597."},{"key":"3483_CR132","unstructured":"Dependency Map (DepMap) portal. https:\/\/depmap.org\/portal\/."},{"key":"3483_CR133","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/modpathol.2015.82","volume":"28","author":"W Sun","year":"2015","unstructured":"Sun W, Chatterjee B, Wang Y, Stevenson HS, Edelman DC, Meltzer PS, et al. Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma. Mod Pathol. 2015;28:1214\u201324.","journal-title":"Mod Pathol"},{"key":"3483_CR134","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/sj.onc.1209958","volume":"26","author":"L Zhang","year":"2007","unstructured":"Zhang L, Wang C. Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. Oncogene. 2007;26:1595\u2013605.","journal-title":"Oncogene"},{"key":"3483_CR135","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bbrc.2007.11.017","volume":"365","author":"K Kikuchi","year":"2008","unstructured":"Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y, et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun. 2008;365:568\u201374.","journal-title":"Biochem Biophys Res Commun"},{"key":"3483_CR136","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jconrel.2016.05.063","volume":"235","author":"V Rengaswamy","year":"2016","unstructured":"Rengaswamy V, Zimmer D, S\u00fcss R, R\u00f6ssler J. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy. J Control Release. 2016;235:319\u201327.","journal-title":"J Control Release"},{"key":"3483_CR137","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/0008-5472.CAN-19-1479","volume":"80","author":"J Ommer","year":"2020","unstructured":"Ommer J, Selfe JL, Wachtel M, O\u2019Brien EM, Laubscher D, Roemmele M, et al. Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes with navitoclax to induce rhabdomyosarcoma cell death. Cancer Res. 2020;80:832\u201342.","journal-title":"Cancer Res"},{"key":"3483_CR138","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/2767-9764.CRC-23-0119","volume":"3","author":"K Nakazawa","year":"2023","unstructured":"Nakazawa K, Shaw T, Song YK, Kouassi-Brou M, Molotkova A, Tiwari PB, et al. Piperacetazine directly binds to the PAX3::FOXO1 fusion protein and inhibits its transcriptional activity. Cancer Res Commun. 2023;3:2030\u201343.","journal-title":"Cancer Res Commun"},{"key":"3483_CR139","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1158\/1535-7163.MCT-13-0277","volume":"12","author":"M Jothi","year":"2013","unstructured":"Jothi M, Mal M, Keller C, Mal AK. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Mol Cancer Ther. 2013;12:2663\u201374.","journal-title":"Mol Cancer Ther"},{"key":"3483_CR140","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1089\/hum.2018.169","volume":"3","author":"S Pellenz","year":"2019","unstructured":"Pellenz S, Phelps M, Tang W, Hovde BT, Sinit RB, Fu W, et al. New human chromosomal sites with \u201csafe harbor\u201d potential for targeted transgene insertion. Hum Gene Ther. 2019;3:814\u201328.","journal-title":"Hum Gene Ther"},{"key":"3483_CR141","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1016\/j.molcel.2022.10.025","volume":"82","author":"S Zhang","year":"2022","unstructured":"Zhang S, Wang J, Liu Q, McDonald WH, Bomber ML, Layden HM, et al. PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets. Mol Cell. 2022;82:4428\u201342.e7.","journal-title":"Mol Cell"},{"key":"3483_CR142","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/mpo.1303","volume":"38","author":"R Dagher","year":"2002","unstructured":"Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 2002;38:158\u201364.","journal-title":"Med Pediatr Oncol"},{"key":"3483_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1265469","volume":"14","author":"WC Lim","year":"2024","unstructured":"Lim WC, Marques Da Costa ME, Godefroy K, Jacquet E, Gragert L, Rondof W, et al. Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers. Front Immunol. 2024;14. 1265469.","journal-title":"Front Immunol"},{"key":"3483_CR144","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1158\/1538-7445.AM2023-6736","volume":"83","author":"D Milewski","year":"2023","unstructured":"Milewski D, Tian M, Kim Y, Wei J, Khan J. Suppression of antigen presentation is a hallmark of pediatric rhabdomyosarcoma. Cancer Res. 2023;83:6736.","journal-title":"Cancer Res"},{"key":"3483_CR145","doi-asserted-by":"publisher","first-page":"10903","DOI":"10.2147\/OTT.S217767","volume":"12","author":"H Dan","year":"2019","unstructured":"Dan H, Zhang S, Zhou Y, Guan Q. DNA methyltransferase inhibitors: catalysts for antitumour immune responses. Onco Targets Ther. 2019;12:10903\u201316.","journal-title":"Onco Targets Ther"},{"key":"3483_CR146","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.18632\/oncotarget.2289","volume":"5","author":"M Kroesen","year":"2014","unstructured":"Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014;5:6558\u201372.","journal-title":"Oncotarget"},{"key":"3483_CR147","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","volume":"20","author":"A Totaro","year":"2018","unstructured":"Totaro A, Panciera T, Piccolo S. YAP\/TAZ upstream signals and downstream responses. Nat Cell Biol. 2018;20:888\u201399.","journal-title":"Nat Cell Biol"},{"key":"3483_CR148","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ccr.2014.05.029","volume":"26","author":"AM Tremblay","year":"2014","unstructured":"Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell. 2014;26:273\u201387.","journal-title":"Cancer Cell"},{"key":"3483_CR149","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1158\/1078-0432.CCR-17-1207","volume":"24","author":"MD Deel","year":"2018","unstructured":"Deel MD, Slemmons KK, Hinson AR, Genadry KC, Burgess BA, Crose LES, et al. The transcriptional coactivator TAZ is a potent mediator of alveolar rhabdomyosarcoma tumorigenesis. Clin Cancer Res. 2018;24:2616\u201330.","journal-title":"Clin Cancer Res"},{"key":"3483_CR150","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1172\/JCI67087","volume":"124","author":"LE Crose","year":"2014","unstructured":"Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, et al. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J Clin Investig. 2014;124:285\u201396.","journal-title":"J Clin Investig"},{"key":"3483_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.108813","volume":"312","author":"L Sanna","year":"2019","unstructured":"Sanna L, Piredda R, Marchesi I, Bordoni V, Forcales SV, Calvisi DF, et al. \u201cVerteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines\u201d. Chem Biol Interact. 2019;312:108813.","journal-title":"Chem Biol Interact"},{"key":"3483_CR152","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173:321\u201337.","journal-title":"Cell"},{"key":"3483_CR153","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","volume":"25","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, et al. Comprehensive molecular characterization of the Hippo signaling pathway in cancer. Cell Rep. 2018;25:1304\u201317.","journal-title":"Cell Rep"},{"key":"3483_CR154","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/pin.12908","volume":"70","author":"GZL Tan","year":"2020","unstructured":"Tan GZL, Saminathan SN, Chang KTE, Odo\u00f1o EG, Kuick CH, Chen H, et al. A rare case of congenital spindle cell rhabdomyosarcoma with TEAD1-NCOA2 fusion: a subset of spindle cell rhabdomyosarcoma with indolent behavior. Pathol Int. 2020;70:234\u20136.","journal-title":"Pathol Int"},{"key":"3483_CR155","doi-asserted-by":"publisher","first-page":"e0140781","DOI":"10.1371\/journal.pone.0140781","volume":"10","author":"KK Slemmons","year":"2015","unstructured":"Slemmons KK, Crose LE, Rudzinski E, Bentley RC, Linardic CM. Role of the YAP oncoprotein in priming Ras-driven rhabdomyosarcoma. PLoS ONE. 2015;10:e0140781.","journal-title":"PLoS ONE"},{"key":"3483_CR156","unstructured":"Study to evaluate VT3989 in patients with metastatic solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT04665206."},{"key":"3483_CR157","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1389450116666150907105756","volume":"17","author":"B Conti","year":"2016","unstructured":"Conti B, Slemmons KK, Rota R, Linardic CM. Recent insights into Notch signaling in embryonal rhabdomyosarcoma. Curr Drug Targets. 2016;17:1235\u201344.","journal-title":"Curr Drug Targets"},{"key":"3483_CR158","doi-asserted-by":"publisher","first-page":"7324","DOI":"10.1158\/1078-0432.CCR-11-1004","volume":"17","author":"BC Belyea","year":"2011","unstructured":"Belyea BC, Naini S, Bentley RC, Linardic CM. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clin Cancer Res. 2011;17:7324\u201336.","journal-title":"Clin Cancer Res"},{"key":"3483_CR159","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/1541-7786.MCR-17-0004","volume":"15","author":"KK Slemmons","year":"2017","unstructured":"Slemmons KK, Crose LES, Riedel S, Sushnitha M, Belyea B, Linardic CM. A novel Notch-YAP circuit drives stemness and tumorigenesis in embryonal rhabdomyosarcoma. Mol Cancer Res. 2017;15:1777\u201391.","journal-title":"Mol Cancer Res"},{"key":"3483_CR160","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","volume":"127","author":"ADJ Pearson","year":"2020","unstructured":"Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, et al. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020;127:52\u201366.","journal-title":"Eur J Cancer"},{"key":"3483_CR161","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, Phase 1-2 trial. Lancet Oncol. 2020;21:541\u201350.","journal-title":"Lancet Oncol"},{"key":"3483_CR162","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre Phase 1-2 study. Lancet Oncol. 2020;21:134\u201344.","journal-title":"Lancet Oncol"},{"key":"3483_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4554-8","volume":"18","author":"G Bertolini","year":"2018","unstructured":"Bertolini G, Bergamaschi L, Ferrari A, Renne SL, Collini P, Gardelli C, et al. PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. BMC Cancer. 2018;18:652.","journal-title":"BMC Cancer"},{"key":"3483_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2451-6","volume":"16","author":"C Kim","year":"2016","unstructured":"Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16:434.","journal-title":"BMC Cancer"},{"key":"3483_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70140","volume":"15","author":"PY Lam","year":"2025","unstructured":"Lam PY, Omer N, Wong JKM, Tu C, Alim L, Rossi GR, et al. Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR. Clin Transl Med. 2025;15:e70140.","journal-title":"Clin Transl Med"},{"key":"3483_CR166","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/209736","volume":"2011","author":"AS Martins","year":"2011","unstructured":"Martins AS, Olmos D, Missiaglia E, Shipley J. Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma. 2011;2011:209736.","journal-title":"Sarcoma"},{"key":"3483_CR167","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-23-0709","volume":"29","author":"S Akshintala","year":"2023","unstructured":"Akshintala S, Sundby RT, Bernstein D, Glod JW, Kaplan RN, Yohe ME, et al. Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma. Clin Cancer Res. 2023;29:3329\u201339.","journal-title":"Clin Cancer Res"},{"key":"3483_CR168","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1470-2045(09)70354-7","volume":"11","author":"D Olmos","year":"2010","unstructured":"Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing\u2019s sarcoma: a Phase 1 expansion cohort study. Lancet Oncol. 2010;11:129\u201335.","journal-title":"Lancet Oncol"},{"key":"3483_CR169","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","volume":"30","author":"S Malempati","year":"2012","unstructured":"Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30:256\u201362.","journal-title":"J Clin Oncol"},{"key":"3483_CR170","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.ejca.2013.06.010","volume":"49","author":"P Sch\u00f6ffski","year":"2013","unstructured":"Sch\u00f6ffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, et al. An open-label, Phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013;49:3219\u201328.","journal-title":"Eur J Cancer"},{"key":"3483_CR171","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pbc.25334","volume":"62","author":"LM Wagner","year":"2015","unstructured":"Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2015;62:440\u20134.","journal-title":"Pediatr Blood Cancer"},{"key":"3483_CR172","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915\u201328.","journal-title":"Nat Rev Cancer"},{"key":"3483_CR173","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/(SICI)1097-0215(19980413)76:2<223::AID-IJC9>3.0.CO;2-Z","volume":"76","author":"T Kalebic","year":"1998","unstructured":"Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer. 1998;76:223\u20137.","journal-title":"Int J Cancer"},{"key":"3483_CR174","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1158\/0008-5472.CAN-08-1712","volume":"68","author":"L Cao","year":"2008","unstructured":"Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008;68:8039\u201348.","journal-title":"Cancer Res"},{"key":"3483_CR175","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/pbc.22367","volume":"54","author":"PJ Houghton","year":"2010","unstructured":"Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010;54:921\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"3483_CR176","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.neo.2015.03.001","volume":"17","author":"X Wan","year":"2015","unstructured":"Wan X, Yeung C, Heske C, Mendoza A, Helman LJ. IGF-1R inhibition activates a YES\/SFK bypass resistance pathway: rational basis for co-targeting IGF-1R and Yes\/SFK kinase in rhabdomyosarcoma. Neoplasia. 2015;17:358\u201366.","journal-title":"Neoplasia"},{"key":"3483_CR177","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.tranon.2016.09.002","volume":"9","author":"CM Heske","year":"2016","unstructured":"Heske CM, Yeung C, Mendoza A, Baumgart JT, Edessa LD, Wan X, et al. The role of PDGFR-\u03b2 activation in acquired resistance to IGF-1R blockade in preclinical models of rhabdomyosarcoma. Transl Oncol. 2016;9:540\u20137.","journal-title":"Transl Oncol"},{"key":"3483_CR178","doi-asserted-by":"publisher","first-page":"e0133152","DOI":"10.1371\/journal.pone.0133152","volume":"10","author":"X Huang","year":"2015","unstructured":"Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, et al. IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. PloS ONE. 2015;10:e0133152.","journal-title":"PloS ONE"},{"key":"3483_CR179","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/pbc.26097","volume":"63","author":"K Dobrenkov","year":"2016","unstructured":"Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung NK. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016;63:1780\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"3483_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100344","volume":"2","author":"S Raman","year":"2021","unstructured":"Raman S, Buongervino SN, Lane MV, Zhelev DV, Zhu Z, Cui H, et al. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Rep Med. 2021;2:100344.","journal-title":"Cell Rep Med"},{"key":"3483_CR181","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351.","journal-title":"Mol Ther"},{"key":"3483_CR182","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a Phase 1 trial. Nat Cancer. 2024;5:880\u201394.","journal-title":"Nat Cancer"},{"key":"3483_CR183","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","volume":"11","author":"M Hegde","year":"2020","unstructured":"Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Commun. 2020;11:3549.","journal-title":"Nature Commun"},{"key":"3483_CR184","unstructured":"A study of patritumab deruxtecan in pediatric participants with relapsed or refractory solid tumors (MK-9999-01C\/LIGHTBEAM-U01). https:\/\/clinicaltrials.gov\/study\/NCT06941272."},{"key":"3483_CR185","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25:2560\u201374.","journal-title":"Clin Cancer Res"},{"key":"3483_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98322-z","volume":"11","author":"T Kanayama","year":"2021","unstructured":"Kanayama T, Miyachi M, Sugimoto Y, Yagyu S, Kikuchi K, Tsuchiya K, et al. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma. Sci Rep. 2021;11:18802.","journal-title":"Sci Rep"},{"key":"3483_CR187","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-20-4221","volume":"27","author":"NM Kendsersky","year":"2021","unstructured":"Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, et al. The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models. Clin Cancer Res. 2021;27:2938\u201346.","journal-title":"Clin Cancer Res"},{"key":"3483_CR188","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.23.02229","volume":"42","author":"N Pinto","year":"2024","unstructured":"Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, et al. STRIvE-02: a first-in-human Phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors. J Clin Oncol. 2024;42:4163\u201372.","journal-title":"J Clin Oncol"},{"key":"3483_CR189","unstructured":"B7H3 CAR T cell immunotherapy for recurrent\/refractory solid tumors in children and young adults. https:\/\/clinicaltrials.gov\/study\/NCT04483778."},{"key":"3483_CR190","unstructured":"B7-H3-specific chimeric antigen receptor autologous T-cell therapy for pediatric patients with solid tumors (3CAR). https:\/\/clinicaltrials.gov\/study\/NCT04897321."},{"key":"3483_CR191","unstructured":"Combination immunotherapy targeting sarcomas. https:\/\/clinicaltrials.gov\/study\/NCT04433221."},{"key":"3483_CR192","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/JIPO-23-18","volume":"7","author":"K Feustel","year":"2024","unstructured":"Feustel K, Martin J, Falchook GS. B7-H3 inhibitors in oncology clinical trials: a review. J Immunother Precis Oncol. 2024;7:53\u201366.","journal-title":"J Immunother Precis Oncol"},{"key":"3483_CR193","doi-asserted-by":"publisher","first-page":"LB061","DOI":"10.1158\/1538-7445.AM2022-LB061","volume":"82","author":"R Gorlick","year":"2022","unstructured":"Gorlick R, Kolb EA, Wang Y, Houghton P, Kurmasheva R, Mosse Y, et al. Evaluation of the in vivo efficacy of the B7-H3 targeting antibody-drug conjugate (ADC) DS7300a: a report from the Pediatric Preclinical In Vivo Resting (PIVOT) program. Cancer Res. 2022;82:LB061.","journal-title":"Cancer Res"},{"key":"3483_CR194","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66545-5","volume":"14","author":"S Chauhan","year":"2024","unstructured":"Chauhan S, Lian E, Habib I, Liu Q, Anders NM, Bugg MM, et al. Entinostat as a combinatorial therapeutic for rhabdomyosarcoma. Sci Rep. 2024;14:18936.","journal-title":"Sci Rep"},{"key":"3483_CR195","doi-asserted-by":"crossref","unstructured":"Federman N, Crane J, Gonzales AM, Arias R, Baroudi M, Singh AS. A Phase 1 dose-escalation\/expansion clinical trial of mocetinostat in combination with vinorelbine in adolescents and young adults with refractory and\/or recurrent rhabdomyosarcoma: interim results. J Clin Oncol. 2022;40:11553.","DOI":"10.1200\/JCO.2022.40.16_suppl.11553"},{"key":"3483_CR196","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan4470","volume":"10","author":"ME Yohe","year":"2018","unstructured":"Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, et al. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Sci Transl Med. 2018;10:eaan4470.","journal-title":"Sci Transl Med"},{"key":"3483_CR197","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1158\/1535-7163.MCT-21-0194","volume":"21","author":"N Garcia","year":"2022","unstructured":"Garcia N, Del Pozo V, Yohe ME, Goodwin CM, Shackleford TJ, Wang L, et al. Vertical inhibition of the RAF-MEK-ERK cascade induces myogenic differentiation, apoptosis, and tumor regression in H\/NRAS(Q61X) mutant rhabdomyosarcoma. Mol Cancer Ther. 2022;21:170\u201383.","journal-title":"Mol Cancer Ther"},{"key":"3483_CR198","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1158\/1078-0432.CCR-13-0850","volume":"19","author":"J Renshaw","year":"2013","unstructured":"Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, et al. Dual blockade of the PI3K\/AKT\/mTOR (AZD8055) and RAS\/MEK\/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res. 2013;19:5940\u201351.","journal-title":"Clin Cancer Res"},{"key":"3483_CR199","unstructured":"FaR-RMS: an overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma (FaR-RMS). https:\/\/www.clinicaltrials.gov\/study\/NCT04625907."},{"key":"3483_CR200","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nrclinonc.2017.59","volume":"14","author":"L Moreno","year":"2017","unstructured":"Moreno L, Pearson ADJ, Paoletti X, Jimenez I, Geoerger B, Kearns PR, et al. Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective. Nat Rev Clin Oncol. 2017;14:497\u2013507.","journal-title":"Nat Rev Clin Oncol"},{"key":"3483_CR201","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/cmdc.202000007","volume":"15","author":"AJ Huhn","year":"2020","unstructured":"Huhn AJ, Gardberg AS, Poy F, Brucelle F, Vivat V, Cantone N, et al. Early-drug discovery efforts towards the identification of EP300\/CBP histone acetyltransferase (HAT) inhibitors. Chem Med Chem. 2020;15:955\u201360.","journal-title":"Chem Med Chem"},{"key":"3483_CR202","first-page":"2869","volume":"54","author":"RJ Davis","year":"1994","unstructured":"Davis RJ, D\u2019Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54:2869\u201372.","journal-title":"Cancer Res"},{"key":"3483_CR203","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/ng0293-113","volume":"3","author":"FG Barr","year":"1993","unstructured":"Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;3:113\u20137.","journal-title":"Nat Genet"},{"key":"3483_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95355-2","volume":"11","author":"JJ Li","year":"2021","unstructured":"Li JJ, Kovach AR, DeMonia M, Slemmons KK, Oristian KM, Chen C, et al. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence. Sci Rep. 2021;11:16505.","journal-title":"Sci Rep"},{"key":"3483_CR205","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.1073\/pnas.94.15.8047","volume":"94","author":"RJ Davis","year":"1997","unstructured":"Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 1997;94:8047\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3483_CR206","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1158\/0008-5472.CAN-12-3947","volume":"73","author":"Z Li","year":"2013","unstructured":"Li Z, Zhang Y, Ramanujan K, Ma Y, Kirsch DG, Glass DJ. Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. Cancer Res. 2013;73:3041\u201350.","journal-title":"Cancer Res"},{"key":"3483_CR207","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade9238","volume":"9","author":"SG Danielli","year":"2023","unstructured":"Danielli SG, Porpiglia E, De Micheli AJ, Navarro N, Zellinger MJ, Bechtold I, et al. Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Sci Adv. 2023;9:eade9238.","journal-title":"Sci Adv"},{"key":"3483_CR208","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ccr.2013.11.015","volume":"24","author":"M Zhang","year":"2013","unstructured":"Zhang M, Linardic CM, Kirsch DG. RAS and ROS in rhabdomyosarcoma. Cancer Cell. 2013;24:689\u201391.","journal-title":"Cancer Cell"},{"key":"3483_CR209","doi-asserted-by":"crossref","unstructured":"Di Carlo D, Chisholm J, Kelsey A, Alaggio R, Bisogno G, Minard-Colin V, et al. Biological role and clinical implications of MYOD1(L122R) mutation in rhabdomyosarcoma. Cancers. 2023;15:1644.","DOI":"10.3390\/cancers15061644"},{"key":"3483_CR210","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1158\/1078-0432.CCR-11-1981","volume":"18","author":"R Tonelli","year":"2012","unstructured":"Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, et al. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res. 2012;18:796\u2013807.","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03483-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03483-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03483-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:03:07Z","timestamp":1785495787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03483-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":210,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8,20]]}},"alternative-id":["3483"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03483-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JSB, CME, SG, EH, FK, GL, Seema Patel, Sam Warburton and DJ are employees of LifeArc. ADJP is a consultant for LifeArc. MC has served on the advisory boards for AstraZeneca\/Alexion, Norgine, Bayer, Roche, Servier and Merck. ADD declares patents related to small-molecule inhibitors and degraders of EP300\/CBP and uses thereof. BH grant funding includes Hoffman-La Roche (Oxford Precision Oncology for Sarcoma protocol). MEH has served on the advisory board for Servier. PK has served on an advisory board for AstraZeneca. CK has or has had sponsored research agreements or collaborations with Roche-Genentech, Eli Lilly, Nurix Therapeutics and Novartis. CK has received unrestricted research grants from Syndax and Cardiff Oncology. CK is also the co-founder of Tio Companies and Teo Therapeutics. Artisan Biopharma is a wholly owned subsidiary of cc-TDI. All other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}